1.
Transplant Proc
; 30(4): 1562-3, 1998 Jun.
Artículo
en Inglés
| MEDLINE
| ID: mdl-9636634
Asunto(s)
Azatioprina/uso terapéutico , Ciclosporina/uso terapéutico , Inmunosupresores/uso terapéutico , Trasplante de Riñón/inmunología , Ácido Micofenólico/análogos & derivados , Trasplante de Páncreas/inmunología , Suero Antilinfocítico/uso terapéutico , Quimioterapia Combinada , Rechazo de Injerto/tratamiento farmacológico , Rechazo de Injerto/patología , Humanos , Muromonab-CD3/uso terapéutico , Ácido Micofenólico/uso terapéutico , Complicaciones Posoperatorias/epidemiología , Estudios Retrospectivos , Tasa de Supervivencia
2.
Clin Transpl
; : 207-19, 1995.
Artículo
en Inglés
| MEDLINE
| ID: mdl-8794267
RESUMEN
Overall, patient and renal allograft survivals after cadaveric transplantation have improved significantly since the incorporation of CsA into the standard immunosuppressive regimen. Overall, patient and renal allograft survivals were significantly better for non-diabetic recipients when compared to diabetic recipients after cadaveric transplantation. Living-donor renal transplant recipients have a better outcome than cadaveric transplant recipients. Cardiovascular disease is the leading cause of death after renal transplantation. Death on dialysis accounted for the second largest number of posttransplant mortalities. Sepsis and malignancy remained the next most important causes of death after renal transplantation.